Our Respiratory Antigen Portfolio

Many COVID-19 assay developers require additional reagents for assay validation. Those submitting to the FDA for Emergency Use Authorization (EUA), for example, are required to satisfy Section J-2 of the “Policy for Coronavirus-2019 disease test (appendix 1)” to demonstrate that their tests do not react with related pathogens, high prevalence disease agents, and normal or pathogenic flora that are reasonably likely to be encountered in a clinical specimen.

To support cross-reactivity screening of immunoassays, The Native Antigen Company offers a portfolio of respiratory antigens that covers many of the organisms recommended for  testing by the FDA and other regulatory bodies. For more information on these products, please click the buttons below: